Olema Pharmaceuticals OLMA 深 沪
等待开盘 09-06 09:30:00 美东时间
8.26
+1.910
+30.08%
华盛通- 最 高8.44
- 今 开6.35
- 成交量 350.33万股
- 最 低 6.35
- 昨 收 6.35
- 总市值 5.67亿
- 52周最高 13.93
- 市盈率 静 --
- 换手率 5.10%
- 52周最低 2.86
- 委 比 8.07%
- 总股本 6863.43万
- 历史最高 60.27
- 量 比 2.62
- 振 幅 32.91%
- 历史最低 2.00
- 每 手 1
- 风险率 3.05%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅403.28%！瑞杰金融首予Kalaris Therapeutics"强烈买入"评级，目标价23美元
今日重点评级关注：花旗：维持Ionis Pharmaceuticals"买入"评级，目标价从69美元升至84美元；Melius Research：上调康明斯评级至"买入"，目标价500美元
09-04 09:49
Pfizer collaboration with Olema may spark future bidding war - analyst
Olema Pharmaceutical's (NASDAQ:OLMA) announcement of a new clinical trial collaboration and supply agreement with Pfizer Inc. (PFE) in metastatic breast cancer may be a sign of a potential bidding war...
09-04 03:26
Oppenheimer Maintains Outperform on Olema Pharmaceuticals, Maintains $22 Price Target
Oppenheimer analyst Matthew Biegler maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Outperform and maintains $22 price target.
09-04 02:55
Olema Oncology to Participate in Upcoming Investor Conferences
Olema Pharmaceuticals, Inc., a biopharmaceutical company focused on developing targeted therapies for breast cancer, announced its participation in several upcoming investor conferences in September 2025. The events include fireside chats and presentations in Boston and New York. Olema is advancing a pipeline of novel therapies, including palazestrant (OP-1250), a Phase 3 clinical trial candidate, and OP-3136, a Phase 1 study drug. More informati...
08-20 20:30
Olema Pharmaceuticals shares are trading higher. The company reported Q2 financial results.
Olema Pharmaceuticals shares are trading higher. The company reported Q2 financ...
08-12 21:00
Citigroup Maintains Buy on Olema Pharmaceuticals, Raises Price Target to $21
Citigroup analyst Yigal Nochomovitz maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and raises the price target from $20 to $21.
08-12 19:28
Olema Pharmaceuticals Q2 EPS $(0.51) Misses $(0.38) Estimate
Olema Pharmaceuticals (NASDAQ:OLMA) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate of $(0.38) by 35.64 percent. This is a 5.56 percent increase over losses of $(0.54) per share
08-12 04:14
Olema Oncology Reports Second Quarter 2025 Financial and Operating Results
Olema Pharmaceuticals reported that the Phase 3 OPERA-01 trial with 90mg once-daily palazestrant continues enrollment, targeting top-line data in 2H 2026. The Phase 3 OPERA-02 trial in combination with ribociclib is set to begin in Q3 2025. Palazestrant's combination data with ribociclib will be presented at ESMO 2025. The company ended Q2 2025 with $361.9 million in cash and marketable securities.
08-11 20:01
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals, Inc. granted stock options to 11 new employees for 322,000 shares, effective June 2, 2025, under its 2022 Inducement Plan. The options, priced at $4.38 per share, vest over four years with monthly installments and a 10-year term, in compliance with Nasdaq Listing Rule 5635(c)(4). The company focuses on targeted therapies for breast cancer, with key candidates in Phase 3 and Phase 1 trials.
06-03 20:30
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Lyra Therapeutics (NASDAQ:LYRA) stock rose 376.8% to $23.5 during Mond...
06-03 01:06
